Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Patent number: 11242390Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.Type: GrantFiled: September 21, 2018Date of Patent: February 8, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Peter Bruenker, Rebecca Croasdale-Wood, Christian Klein, Juergen Michael Schanzer, Kay-Gunnar Stubenrauch, Pablo Umana, Martina Geiger, Eric Sullivan, Jigar Patel
-
Patent number: 11207324Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.Type: GrantFiled: April 27, 2018Date of Patent: December 28, 2021Assignee: Seagen Inc.Inventors: Scott Peterson, Luke Walker
-
Patent number: 11202781Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.Type: GrantFiled: January 17, 2019Date of Patent: December 21, 2021Assignee: Epizyme, Inc.Inventors: Heike Keilhack, Sarah Kathleen Knutson, Danielle Johnston Blackwell
-
Patent number: 11186817Abstract: The present invention relates to an optimal medium for growing a cell line auxotrophic for tetrahydrofolate (THF) and producing a desired material in the cell with high efficiency. In particular, the present invention provides a method for enhancing cell growth by adding tetrahydrofolate (THF), or a precursor or derivative thereof into a chemical composition cell medium.Type: GrantFiled: February 23, 2015Date of Patent: November 30, 2021Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)Inventors: Hong-Woo Park, Bong Gyun Kim
-
Patent number: 11186641Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents.Type: GrantFiled: March 16, 2017Date of Patent: November 30, 2021Assignee: OSLO UNIVERSITETSSYKEHUS HFInventor: Anders Tveita
-
Patent number: 11129904Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.Type: GrantFiled: March 14, 2019Date of Patent: September 28, 2021Assignee: Eisai R&D Managment Co., Ltd.Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
-
Patent number: 11116846Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.Type: GrantFiled: October 21, 2020Date of Patent: September 14, 2021Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Serengulam V. Govindan
-
Patent number: 11111525Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.Type: GrantFiled: March 19, 2018Date of Patent: September 7, 2021Assignees: Applied Biosystems, LLC, Agilent Technologies, Inc.Inventors: Kirsten Vang Nielsen, Jens Hyldig-Nielsen, Brett F. Williams
-
Patent number: 11066460Abstract: The present invention relates to vectors suitable for use in displaying proteins on the surface of bacteriophage M13 as fusion constructs with the surface protein P.III, bacteriophage M13 particles comprising a mutated P.III protein on the phage coat surface, as well as methods for producing bacteriophage M13 particles and methods for transfecting or infecting a host cell comprising the vectors and bacteriophage of the invention.Type: GrantFiled: November 18, 2016Date of Patent: July 20, 2021Assignee: Eli Lilly and CompanyInventor: Sepideh Afshar
-
Patent number: 11058708Abstract: Galectin-3 is a pro-inflammatory molecule functioning as a cytokine hub, and also regulates unfolded protein responses (UPR) and ER stress. Thus, galectin-3 serves as a target for ameliorating inflammatory diseases such as allergic inflammation and diabetic inflammation and insulin resistance. RNA interference of endogenous galectin-3 expression, upregulates IL-12, IL-10 while downregulating IL-23 production, which offers protection against allergic inflammation. In addition, endogenous galectin-3 knockdown causes upregulation of XBP1, alleviating ER stress. Together, upregulated XBP1 and IL-10 offer protection against obesity-induced inflammation. Therefore, the embodiment of the invention resides in RNA interference of endogenous galectin-3 in appropriate cell types in order to rectify allergic and/or diabetic inflammation.Type: GrantFiled: September 19, 2011Date of Patent: July 13, 2021Inventor: Swey-Shen Chen
-
Patent number: 11046763Abstract: Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRP?.Type: GrantFiled: January 8, 2015Date of Patent: June 29, 2021Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Kipp Andrew Weiskopf, Julien Sage, Irving L. Weissman
-
Patent number: 11034775Abstract: The present disclosure involves biologically active proteins termed cysteine-optimized multimerizing stradomers. Thus, the present disclosure provides compositions and methods providing anti-autoimmune and anti-inflammatory activities, useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.Type: GrantFiled: June 7, 2017Date of Patent: June 15, 2021Assignee: GLIKNIK INC.Inventors: Henrik Olsen, David S. Block
-
Patent number: 10994033Abstract: The invention relates to water soluble 18F-prosthetic groups and the synthesis and use 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.Type: GrantFiled: May 31, 2017Date of Patent: May 4, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: David Donnelly, David K. Leung
-
Patent number: 10987435Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies. The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.Type: GrantFiled: August 15, 2017Date of Patent: April 27, 2021Assignees: INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, NANOHInventors: François Lux, Olivier Tillement, Maxime Saint Jean, Pierre Mowat, Pascal Perriat, Stéphane Roux, Anna Mignot
-
Patent number: 10981988Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: February 6, 2018Date of Patent: April 20, 2021Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars Van Den Berg
-
Patent number: 10968279Abstract: Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.Type: GrantFiled: May 5, 2017Date of Patent: April 6, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Achal Pashine, Guodong Chen
-
Patent number: 10961308Abstract: Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of Embigin to a recipient subject and can also optionally include administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of Embigin to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described.Type: GrantFiled: June 29, 2016Date of Patent: March 30, 2021Assignees: THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: David T. Scadden, Lev Silberstein, Peter Kharchenko
-
Patent number: 10960037Abstract: A method of treating neurological condition in a subject by administration of a neuroprotective composition of a mixture of two or more triterpenes. Alzheimer's disease, Huntington's disease, stroke or Parkinson's disease are treated by administering a therapeutically effective amount of the neuroprotective composition to a subject.Type: GrantFiled: April 17, 2019Date of Patent: March 30, 2021Assignee: PHOENIX BIOTECHNOLOGY, INC.Inventors: Otis C. Addington, Robert A. Newman
-
Patent number: 10954305Abstract: The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.Type: GrantFiled: April 24, 2019Date of Patent: March 23, 2021Assignee: Immunomedics, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 10953107Abstract: Described herein are methods and compositions related to compositions comprising combinations of V/K-type and V/E-type docking peptides and uses thereof, e.g., to deliver therapeutic agents to treat certain conditions such as cancer, infection, or trauma.Type: GrantFiled: June 14, 2019Date of Patent: March 23, 2021Assignee: Trustees of Boston UniversityInventors: Mark W. Grinstaff, Christopher Gromisch, Victoria Herrera, Nelson Ruiz-Opazo
-
Patent number: 10940204Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.Type: GrantFiled: August 1, 2016Date of Patent: March 9, 2021Assignee: Research Institute at Nationwide Children's HospitalInventors: Lauren O. Bakaletz, Steven D. Goodman
-
Patent number: 10905752Abstract: The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.Type: GrantFiled: June 16, 2016Date of Patent: February 2, 2021Assignee: VAXIMM AGInventor: Heinz Lubenau
-
Patent number: 10894986Abstract: The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.Type: GrantFiled: May 21, 2015Date of Patent: January 19, 2021Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Jun Luo, George Steven Bova, William Isaacs, Thomas Dunn, Rong Hu
-
Patent number: 10889651Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.Type: GrantFiled: July 31, 2018Date of Patent: January 12, 2021Assignee: Genentech, Inc.Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
-
Patent number: 10874728Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.Type: GrantFiled: March 21, 2016Date of Patent: December 29, 2020Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: George Coukos, Andrea Facciabene
-
Patent number: 10849986Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.Type: GrantFiled: April 8, 2020Date of Patent: December 1, 2020Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Serengulam V. Govindan
-
Patent number: 10780179Abstract: The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin D, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells. The uses of such conjugates for the treatment of cancer are described.Type: GrantFiled: March 18, 2016Date of Patent: September 22, 2020Assignee: IMMUNOBIOCHEM CORPORATIONInventor: Anton Neschadim
-
Patent number: 10765625Abstract: Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes.Type: GrantFiled: March 14, 2017Date of Patent: September 8, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Nicholas Cox, Jennifer R. Cochran, Mark Smith, James R. Kintzing
-
Patent number: 10751284Abstract: Provided herein are tumor associated macrophage (TAM)-targeting liposome having a lipid bilayer; a targeting agent associated with the lipid bilayer, wherein the targeting agent comprises an antibody or fragment thereof that selectively binds a tumor associated macrophage; and a cytotoxic agent associated with the lipid bilayer, wherein the cytotoxic agent depletes tumor associated macrophages at or near the site of a tumor. Also provided are pharmaceutical compositions comprising the TAM-targeting liposomes and methods of treating a subject with cancer with the compositions.Type: GrantFiled: August 15, 2017Date of Patent: August 25, 2020Assignee: VERILY LIFE SCIENCES LLCInventors: Stephen Morton, Graziella Solinas
-
Patent number: 10745346Abstract: Some novel compounds are provided in this disclosure. These novel compounds have potential SHP-1 agonist activity for being used in treating cancer.Type: GrantFiled: August 31, 2016Date of Patent: August 18, 2020Inventors: Kuen-Feng Chen, Chung-Wai Shiau
-
Patent number: 10739349Abstract: The present invention provides, among other aspects, stabilized chromophoric nanoparticles. In certain embodiments, the chromophoric nanoparticles provided herein are rationally functionalized with a pre-determined number of functional groups. In certain embodiments, the stable chromophoric nanoparticles provided herein are modified with a low density of functional groups. In yet other embodiments, the chromophoric nanoparticles provided herein are conjugated to one or more molecules. Also provided herein are methods for making rationally functionalized chromophoric nanoparticles.Type: GrantFiled: May 27, 2016Date of Patent: August 11, 2020Assignee: University of Washington through its Center for CommercializationInventors: Daniel T. Chiu, Changfeng Wu, Xuanjun Zhang, Jiangbo Yu, Fangmao Ye
-
Patent number: 10736975Abstract: A patient specific therapeutic composition provided in a single dose container, the total volume of which may be administered to a patient in a single treatment session. The composition includes a monoclonal antibody having a labeled fraction and an unlabeled fraction, and a pharmaceutically acceptable carrier. The label may be any of a radioisotope or a drug such as a chemotherapeutic or cytotoxic agent. The amount of the monoclonal antibody and any conjugated label molecule may depend on at least one patient specific parameter selected from a patient weight, a patient age, a patient height, a patient gender, a patient medical condition, and a patient medical history. Methods of administration, production, and articles of manufacture comprising the patient specific therapeutic composition are also disclosed.Type: GrantFiled: May 20, 2016Date of Patent: August 11, 2020Assignee: Actinium Pharmaceuticals, Inc.Inventors: Kaushik J. Dave, Yulian Zhang
-
Patent number: 10651410Abstract: The present disclosure relates to an organic light emitting device including: a first electrode; a second electrode provided to face the first electrode; and an electron transport layer, an emitting layer and a hole transport layer provided between the first electrode and the second electrode, and the emitting layer contains doped protein quantum dots.Type: GrantFiled: December 6, 2019Date of Patent: May 12, 2020Assignee: Research & Business Foundation Sungkyunkwan UniversityInventors: June Kyun Park, Yong Han Roh, Sang Hyun Lee, Byung Chan Seo, Jae Won Jeong
-
Patent number: 10626176Abstract: Provided herein are embodiments relating to therapeutic applications of B7-H4 antibodies.Type: GrantFiled: October 30, 2015Date of Patent: April 21, 2020Assignee: JOUNCE THERAPEUTICS, INC.Inventors: Sriram Sathyanarayanan, Tatiana Novobrantseva, Virna Cortez-Retamozo
-
Patent number: 10604558Abstract: The disclosure encompasses resurfaced cell-penetrating nanobodies and their methods of use. The resurfacing of nanobodies with positively-charged amino acids facilitates their penetration into a cell and allows targeting of a specific intracellular protein.Type: GrantFiled: January 4, 2017Date of Patent: March 31, 2020Assignee: Colorado State University Research FoundationInventors: Brian R. McNaughton, Virginia J. Bruce
-
Patent number: 10604577Abstract: The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.Type: GrantFiled: October 20, 2016Date of Patent: March 31, 2020Assignee: Allakos Inc.Inventors: Christopher Robert Bebbington, Nenad Tomasevic, Rustom Falahati
-
Patent number: 10590422Abstract: The present invention is directed to a method of treating cancer using interfering RNA duplexes to mediate gene silencing. The present invention is also directed to interfering RNA duplexes and vectors encoding such interfering RNA duplexes.Type: GrantFiled: June 14, 2017Date of Patent: March 17, 2020Assignee: PHYZAT BIOPHARMACEUTICALS, LDA.Inventor: Patricio Soares da Silva
-
Patent number: 10591492Abstract: Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.Type: GrantFiled: March 4, 2019Date of Patent: March 17, 2020Assignee: Janssen Pharmaceutica NVInventors: Hartmuth Christian Kolb, Gallen Triana-Baltzer, John Randall Slemmon
-
Patent number: 10568951Abstract: The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.Type: GrantFiled: November 13, 2014Date of Patent: February 25, 2020Assignee: FORMYCON AGInventor: Rainer Sigl
-
Patent number: 10570195Abstract: An antibody or fragment thereof capable of binding to a neurotoxic tau protein. The neurotoxic tau protein includes a phosphorylation site at threonine residue 231 in AT180 domain of tau proteins and an amino acid substitution of proline residue 232 to glycine (P232G) in AT180 domain of tau proteins.Type: GrantFiled: March 11, 2019Date of Patent: February 25, 2020Inventor: Koorosh Shahpasand
-
Patent number: 10562961Abstract: The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.Type: GrantFiled: November 20, 2017Date of Patent: February 18, 2020Assignee: Astute Medical, Inc.Inventors: Ravi A. Vijayendran, Srivatsa Venkatasubbarao
-
Patent number: 10556024Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolalebed proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.Type: GrantFiled: November 13, 2014Date of Patent: February 11, 2020Assignees: Whitehead Institute for Biomedical Research, The General Hospital CorporationInventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
-
Patent number: 10538534Abstract: Analogs of largazole are described herein. Methods of treating cancer, blood disorders, autoimmune disease, and Alzheimer's Disease using largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.Type: GrantFiled: March 4, 2016Date of Patent: January 21, 2020Assignees: Colorado State University Research Foundation, Dana-Farber Cancer Institute, Inc., University of Notre Dame du LacInventors: Robert M. Williams, James E. Bradner, Dane Clausen, Olaf G. Wiest, Le Zhao, Christine Elizabeth Dunne
-
Patent number: 10456466Abstract: The present invention relates to antibodies which specifically bind vascular endothelial growth factor (VEGF), in particular heavy-chain antibodies, and more particularly single-domain antibodies. The present invention also relates to a method of producing the antibodies and the therapeutic uses thereof.Type: GrantFiled: January 6, 2015Date of Patent: October 29, 2019Assignee: Zhuhai Essex Bio-Pharmaceutical Co., Ltd.Inventors: Haizhou Fang, Wei Qu, Zanshun Zheng, Lanfang Zhuang, Xinzhi Wang
-
Patent number: 10406179Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.Type: GrantFiled: August 26, 2015Date of Patent: September 10, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf, Aaron Michael Ring, Akanksha Chhabra, Peter Schnorr
-
Patent number: 10383878Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).Type: GrantFiled: October 4, 2016Date of Patent: August 20, 2019Assignees: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBHInventors: Thore Hettmann, Reimar Abraham, Sabine Blum, Suguru Ueno
-
Patent number: 10358503Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the {p}Ser404 Epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: August 11, 2016Date of Patent: July 23, 2019Assignee: New York UniversityInventor: Einar Sigurdsson
-
Patent number: 10352933Abstract: Detection and quantification of microbial colonization and biofilm formation on orthopedic explants would be important for deciding treatment interventions at the time of surgery. Methods and Systems for such treatments are shown that utilize various steps and kits to quickly generate confocal laser-scanning microscopy (CLSM) images to allow for the detection and quantification. The explants are prepared by applying antibodies of both gram-positive and grain-negative for at least one period of time.Type: GrantFiled: December 17, 2015Date of Patent: July 16, 2019Assignee: Rhode Island HospitalInventors: Dioscaris Garcia, Christopher T. Born, John Jarrell
-
Patent number: 10344087Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.Type: GrantFiled: February 13, 2014Date of Patent: July 9, 2019Assignee: INNATE PHARMAInventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
-
Patent number: RE48787Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.Type: GrantFiled: April 9, 2019Date of Patent: October 26, 2021Assignee: UCB Biopharma SRLInventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage